{"nctId":"NCT02515656","briefTitle":"Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis","startDateStruct":{"date":"2015-09"},"conditions":["Vaginitis"],"count":661,"armGroups":[{"label":"POLYGYNAX®","type":"EXPERIMENTAL","interventionNames":["Drug: POLYGYNAX®"]},{"label":"miconazole + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: GYNODAKTARIN®","Drug: Placebo"]}],"interventions":[{"name":"POLYGYNAX®","otherNames":[]},{"name":"GYNODAKTARIN®","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with an abnormal vaginal discharge associated with one (or more) functional vaginal complaints: vaginal burning and/or vaginal pain and/or vaginal irritation clinically evoking an infectious vaginitis:\n\n  * bacterial vaginitis\n  * non-specific vaginitis (atypical symptoms)\n  * mixed vaginitis (i.e. suprainfected fungal vaginitis) and able to receive an empirical local treatment\n\nExclusion Criteria:\n\n1. Recurrent patient; i.e. a patient who has had at least 4 episodes of infectious vaginitis in the 12 months prior to inclusion\n2. Vaginal infection justifying systemic therapy\n3. History of atrophic vaginitis or suspected atrophic vaginitis at inclusion\n4. Patient presenting with signs of genital herpes or signs of non-infectious vulvar pathology (vulvodynia, psoriasis, eczema, lichen sclerosus, lichen planus, contact dermatitis, candida intertrigo, vulval intraepithelial neoplasia (VIN))\n5. Patient with current Sexually Transmitted Infection (STI) and/or patients with clinical suspicion of STI\n6. Disease or concomitant treatment that could cause decreased immunity (i.e. diabetes mellitus, corticosteroids treatments)\n7. Systemic anti-infective treatment (antibiotic, antifungal) within two weeks prior to inclusion\n8. Patient menstruating or patient with menometrorrhagia due to hormonal imbalance at the time of inclusion\n9. Pregnant or lactating women or delivery within last 1 month","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit","description":"* Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation).\n* Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.\n\nNot considered as \"Treatment Failure\":\n\n* The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1.\n* Patients presenting with only vulvar complaints not considered as related to infectious vaginitis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"268","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary","description":"This outcome was evaluated using a Visual Analogue Scale (VAS) completed by the patient.\n\nThe scale measured the level of each vaginal symptom experienced during the day (vaginal discharge, vaginal burning, vaginal pain and vaginal irritation).\n\nScale ranges = 0 to 100 0=none symptom 100=maximum intensity of symptom Time points used in the calculation= D1 to D14","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.43","spread":null},{"groupId":"OG001","value":"29.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.89","spread":null},{"groupId":"OG001","value":"27.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.93","spread":null},{"groupId":"OG001","value":"17.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.37","spread":null},{"groupId":"OG001","value":"28.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.96","spread":null},{"groupId":"OG001","value":"28.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Change in Vaginal Discharge Assessed by the Investigator","description":"The vaginal discharge is assessed by the investigator by using a score:\n\n0=absent\n\n1. mild: insufficient for speculum collection\n2. moderate: sufficient for speculum collection\n3. abundant: visible at the introitus even before speculum introduction.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"280","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit","description":"Success and Failure (same definition as the primary outcome measure)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Global Satisfaction","description":"The investigator filled the satisfaction questionnaire during the end of treatment visit.\n\nSix ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"252","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"40","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Satisfaction","description":"The patient filled the satisfaction questionnaire on her patient's diary at home the eve of the End of Treatment Visit.\n\nSix ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"233","spread":null}]},{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"63","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":325},"commonTop":["Headache"]}}}